The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
Adeona Pharmaceuticals, Inc. (Adeona) is a development-stage pharmaceutical company developing medicines for central nervous systems diseases. Trimesta (estriol) is an investigational oral drug for the treatment of relapsingremitting multiple sclerosis. ZinthioneinTM ZC (zinc cysteine) is an oral, gastro-retentive, sustained-release medical food candidate being developed for the dietary management of Alzheimer’s disease and mild cognitive impairment. In December of 2009, Adeona initiated a 60-patient clinical study. Effirma (flupirtine) is an investigational oral drug for the treatment of fibromyalgia syndrome. dnaJP1 (hsp peptide) is an investigational oral drug for the treatment of rheumatoid arthritis. CD4 Inhibitor 802-2 (cyclic heptapeptide) is an investigational drug for the prevention of severe graft-versus-host disease. On July 10, 2009 the Company acquired Hart Lab, LLC.